MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Maternal embryonic leucine pull chain kinase (MELK) promotes lung adenocarcinoma (LUAD) growth and metastasis by upregulating EZH2 and downregulating LATS2. Inhibiting MELK or EZH2, or overexpressing LATS2, restrains LUAD progression.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Lung adenocarcinoma (LUAD) is a major cause of cancer-related mortality.
- The molecular mechanisms driving LUAD growth and metastasis require further elucidation.
- Maternal embryonic leucine pull chain kinase (MELK) has been implicated in various cancers.
Purpose Of The Study
- To investigate the role of MELK in the progression of lung adenocarcinoma.
- To identify the molecular interactions and pathways regulated by MELK in LUAD.
- To assess the therapeutic potential of targeting MELK in LUAD.
Main Methods
- Bioinformatic analysis of LUAD gene expression data (GEPIA database).
- Expression analysis of MELK, EZH2, and LATS2 in clinical LUAD samples and cell lines.
- Co-immunoprecipitation (Co-IP), CHX tracking, ubiquitination, and chromatin immunoprecipitation (ChIP) assays.
- In vitro cell proliferation, invasion, and apoptosis assays.
- In vivo tumor formation study in a xenograft mouse model.
Main Results
- MELK and EZH2 were significantly upregulated in LUAD tissues, while LATS2 was downregulated.
- MELK physically interacted with EZH2, inhibiting EZH2 ubiquitination and degradation.
- EZH2 mediated H3K27me3 modification at the LATS2 promoter, leading to decreased LATS2 expression.
- Silencing MELK or EZH2, or overexpressing LATS2, inhibited LUAD cell proliferation and invasion, and promoted apoptosis.
- Targeting MELK or EZH2, or increasing LATS2, suppressed tumor growth in vivo.
Conclusions
- MELK promotes LUAD progression by interacting with EZH2 to suppress LATS2 expression.
- The MELK/EZH2/LATS2 axis represents a potential therapeutic target for lung adenocarcinoma.
- Understanding this pathway provides insights into LUAD tumorigenesis and metastasis.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...